Results 1 to 10 of about 525,581 (319)

Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic [PDF]

Pulmonary Circulation, 2020
The COVID-19 pandemic presents many unique challenges when caring for patients with pulmonary hypertension. The COVID-19 pandemic has altered routine standard of care practice and the acute management particularly for those patients with pulmonary ...
John J. Ryan, Lana Melendres-Groves, Roham T. Zamanian, Ronald J. Oudiz, Murali Chakinala, Erika B. Rosenzweig, Mardi Gomberg-Maitland   +6 more
doaj   +4 more sources

Clinical heterogeneity of Pulmonary Arterial Hypertension associated with variants in TBX4. [PDF]

PLoS ONE, 2020
BACKGROUND:The knowledge of hereditary predisposition has changed our understanding of Pulmonary Arterial Hypertension. Genetic testing has been widely extended and the application of Pulmonary Arterial Hypertension specific gene panels has allowed its ...
Ignacio Hernandez-Gonzalez, Jair Tenorio, Julian Palomino-Doza, Amaya Martinez Meñaca, Rafael Morales Ruiz, Mauro Lago-Docampo, María Valverde Gomez, Javier Gomez Roman, Ana Belén Enguita Valls, Carmen Perez-Olivares, Diana Valverde, Joan Gil Carbonell, Elvira Garrido-Lestache Rodríguez-Monte, Maria Jesus Del Cerro, Pablo Lapunzina, Pilar Escribano-Subias   +15 more
doaj   +2 more sources

Cardiac sympathetic dysfunction in pulmonary arterial hypertension: lesson from left-sided heart failure [PDF]

Pulmonary Circulation, 2019
Sympathetic nervous system hyperactivity has a well-recognized role in the pathophysiology of heart failure with reduced left ventricular ejection fraction.
Valentina Mercurio, Teresa Pellegrino, Giorgio Bosso, Giacomo Campi, Paolo Parrella, Valentina Piscopo, Carlo G. Tocchetti, Paul M. Hassoun, Mario Petretta, Alberto Cuocolo, Domenico Bonaduce   +10 more
doaj   +2 more sources

Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report [PDF]

Cardiovascular Ultrasound, 2005
background Interferon alpha2 is widely used in hepatitis and high-risk melanoma. Interferon-induced pulmonary arterial hypertension as a side effect is rare.
Baumann Gert, Sterry Wolfram, Eddicks Stephan, Hofmann Maja A, Borges Adrian C, Kiecker Felix, Jochmann Nicoline, Trefzer Uwe   +7 more
doaj   +4 more sources

Transcriptional profiling of lung cell populations in idiopathic pulmonary arterial hypertension

Pulmonary Circulation, 2020
Despite recent improvements in management of idiopathic pulmonary arterial hypertension, mortality remains high. Understanding the alterations in the transcriptome–phenotype of the key lung cells involved could provide insight into the drivers of ...
Didem Saygin, Tracy Tabib, Humberto E.T. Bittar, Eleanor Valenzi, John Sembrat, Stephen Y. Chan, Mauricio Rojas, Robert Lafyatis   +7 more
doaj   +2 more sources

Clinical phenotyping of plasma thrombospondin-2 reveals relationship to right ventricular structure and function in pulmonary hypertension

ERJ Open Research, 2023
Background Converging evidence from proteogenomic analyses prioritises thrombospondin-2 (TSP2) as a potential biomarker for idiopathic or heritable pulmonary arterial hypertension (PAH).
Anna M. Dittrich, Julia Mienert, Julian Pott, Lena Engels, Christoph Sinning, Jan K. Hennigs, Hans Klose, Lars Harbaum   +7 more
doaj   +1 more source

Residual risk identified in routine noninvasive follow-up assessments in pulmonary arterial hypertension

ERJ Open Research, 2023
Background The 2022 ESC/ERS guidelines on pulmonary hypertension recommend noninvasive risk assessments based on three clinical variables during follow-up in patients with pulmonary arterial hypertension (PAH).
Jonna Ostermann, Julian Pott, Jan K. Hennigs, Kevin Roedl, Christoph Sinning, Lars Harbaum, Hans Klose   +6 more
doaj   +1 more source

Transcription factors in the pathogenesis of pulmonary arterial hypertension—Current knowledge and therapeutic potential

Frontiers in Cardiovascular Medicine, 2023
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pulmonary vascular resistance and pulmonary artery pressure. Mortality remains high in severe cases despite significant advances in management and pharmacotherapy.
Jakob Körbelin, Julius Klein, Julius Klein, Christiane Matuszcak, Christiane Matuszcak, Johannes Runge, Johannes Runge, Lars Harbaum, Hans Klose, Jan K. Hennigs, Jan K. Hennigs   +10 more
doaj   +1 more source

The Paradox of Pulmonary Vascular Resistance: Restoration of Pulmonary Capillary Recruitment as a \u3ci\u3eSine Qua Non\u3c/i\u3e for True Therapeutic Success in Pulmonary Arterial Hypertension [PDF]

, 2022
Exercise-induced increases in pulmonary blood flow normally increase pulmonary arterial pressure only minimally, largely due to a reserve of pulmonary capillaries that are available for recruitment to carry the flow.
Catravas, John D., Fox, Benjamin D., Giovinazzo, Michele, Langleben, David, Messas, Nathan, Orfanos, Stylianos E.   +5 more
core   +2 more sources

Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension

European Respiratory Journal, 2022
Background In participants with pulmonary arterial hypertension, 24 weeks of sotatercept resulted in a significantly greater reduction from baseline in pulmonary vascular resistance than placebo.
M. Humbert, V. McLaughlin, J. Gibbs, M. Gomberg-Maitland, M. Hoeper, I. Preston, Rogério Souza, A. Waxman, H. Ghofrani, P. Escribano Subías, J. Feldman, G. Meyer, D. Montani, K. Olsson, S. Manimaran, J. de Oliveira Pena, D. Badesch   +16 more
semanticscholar   +1 more source